PDBsum entry 1jnp

Go to PDB code: 
protein Protein-protein interface(s) links
Immune system PDB id
Protein chains
101 a.a. *
Waters ×49
* Residue conservation analysis
PDB id:
Name: Immune system
Title: Crystal structure of murine tcl1 at 2.5 resolution
Structure: T-cell leukemia/lymphoma protein 1a. Chain: a, b. Synonym: p14 tcl1 protein, tcl1 oncogene, tcl-1 protein. Engineered: yes. Mutation: yes
Source: Mus musculus. House mouse. Organism_taxid: 10090. Expressed in: escherichia coli. Expression_system_taxid: 562
2.50Å     R-factor:   0.226     R-free:   0.236
Authors: J.M.Petock,I.Y.Torshin,Y.F.Wang,G.C.Dubois,C.M.Croce, R.W.Harrison,I.T.Weber
Key ref:
J.M.Petock et al. (2001). Structure of murine Tcl1 at 2.5 A resolution and implications for the TCL oncogene family. Acta Crystallogr D Biol Crystallogr, 57, 1545-1551. PubMed id: 11679718 DOI: 10.1107/S090744490101352X
24-Jul-01     Release date:   07-Nov-01    
Go to PROCHECK summary

Protein chains
Pfam   ArchSchema ?
P56280  (TCL1A_MOUSE) -  T-cell leukemia/lymphoma protein 1A
116 a.a.
101 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     cytoplasm   6 terms 
  Biological process     stem cell maintenance   1 term 


DOI no: 10.1107/S090744490101352X Acta Crystallogr D Biol Crystallogr 57:1545-1551 (2001)
PubMed id: 11679718  
Structure of murine Tcl1 at 2.5 A resolution and implications for the TCL oncogene family.
J.M.Petock, I.Y.Torshin, Y.F.Wang, G.C.Du Bois, C.M.Croce, R.W.Harrison, I.T.Weber.
Tcl1 and Mtcp1, members of the Tcl1 family, are implicated in T-cell prolymphocytic leukemia. The crystal structure of a dimer of murine Tcl1 has been determined at 2.5 A resolution with an R factor of 0.225. Murine Tcl1, human Tcl1 and Mtcp1 share very similar subunit structures, with RMS differences of 0.6 and 1.4 A for C(alpha) atoms, respectively, while the sequences share 50 and 36% identity, respectively. These structures fold into an eight-stranded beta-barrel of unique topology and high internal symmetry of 1.1-1.3 A for the two halves of human and murine Tcl1 and 1.7 A for Mtcp1, despite the low 12-13% sequence identity. The molecular surfaces of all three structures showed a common planar region which is likely to be involved in protein-protein interactions.
  Selected figure(s)  
Figure 2.
Figure 2 Structural comparisons of Tcl1 family members. (a) Superposition of C[ ]atoms of two subunits of murine Tcl1 (the two subunits are shown in black and gray). (b) Superimposed C[ ]atoms of mTcl1 (subunit 1 in black), hTcl1 (white) and hMtcp1 (gray).
Figure 4.
Figure 4 Molecular-surface analysis. The extensive planar surface is shown in the same orientation for the subunits of mTcl1, hTcl1 and hMtcp1. Protein surfaces were generated with the program WebLab ViewerLite using a probe radius of 2.5 (Molecular Simulations Inc.). Regions of negative electrostatic potential are colored red and positive regions are blue. (a) mTcl1, side view; (b) mTcl1, front view; (c) hTcl1, side view; (d) hTcl1, front view; (e) hMtcp1, side view; (f) hMtcp1, front view.
  The above figures are reprinted by permission from the IUCr: Acta Crystallogr D Biol Crystallogr (2001, 57, 1545-1551) copyright 2001.  
  Figures were selected by the author.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
16056259 M.A.Teitell (2005).
The TCL1 family of oncoproteins: co-activators of transformation.
  Nat Rev Cancer, 5, 640-648.  
16078861 Z.Zhang, M.Li, E.R.Rayburn, D.L.Hill, R.Zhang, and H.Wang (2005).
Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.
  Am J Pharmacogenomics, 5, 247-257.  
12962701 R.B.Lock (2003).
TCL1: a new drug target in lymphoid and germ-cell malignancies?
  Int J Biochem Cell Biol, 35, 1614-1618.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.